Background: Radiofrequency ablation (RFA) is an emerging treatment for patients with locally advanced pancreatic carcinoma (LAPC) and can be combined with radiochemotherapy (RCT), and intra-arterial plus systemic chemotherapy (IASC). Methods: This observational study compared two groups of patients with LAPC treated either with primary RFA (group 1) or RFA following primary treatment (group 2): systemic chemotherapy and/or RCT and/or IASC Group 1 included 47 patients submitted to RFA like up-front treatment; Group 2 included 60 patients submitted to RFA after other specified treatments. Results: Between February 2007 and May 2010, 107 consecutive patients were treated by RFA. There were 47 patients in group 1 and 60 in group 2. Median overall survival (OS) was 25.6 months, 14.7 months in Group 1 and 25.6 months in group 2 (p= 0.004) Patients treated with RFA, RCT and IASC (triple approach strategy) had an OS of 34.0 months. Conclusion: RFA after alternative primary treatment was associated with prolonged survival. This was further prolonged in selected patients using a triple approach strategy. Further evaluation of this approach seems warranted

Combined modality treatment for patients with locally advanced pancreatic adenocarcinoma

FRIGERIO, Isabella;SALVIA, Roberto;GIARDINO, Alessandro;AURIEMMA, Alessandra;BASSI, Claudio
2012-01-01

Abstract

Background: Radiofrequency ablation (RFA) is an emerging treatment for patients with locally advanced pancreatic carcinoma (LAPC) and can be combined with radiochemotherapy (RCT), and intra-arterial plus systemic chemotherapy (IASC). Methods: This observational study compared two groups of patients with LAPC treated either with primary RFA (group 1) or RFA following primary treatment (group 2): systemic chemotherapy and/or RCT and/or IASC Group 1 included 47 patients submitted to RFA like up-front treatment; Group 2 included 60 patients submitted to RFA after other specified treatments. Results: Between February 2007 and May 2010, 107 consecutive patients were treated by RFA. There were 47 patients in group 1 and 60 in group 2. Median overall survival (OS) was 25.6 months, 14.7 months in Group 1 and 25.6 months in group 2 (p= 0.004) Patients treated with RFA, RCT and IASC (triple approach strategy) had an OS of 34.0 months. Conclusion: RFA after alternative primary treatment was associated with prolonged survival. This was further prolonged in selected patients using a triple approach strategy. Further evaluation of this approach seems warranted
2012
Pancreas; Cancer; Radiofrequency ablation; Adjuvant chemotherapy
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11562/731562
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 62
  • ???jsp.display-item.citation.isi??? 57
social impact